Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;98(2):E20-E23.
doi: 10.1002/ajh.26780. Epub 2022 Nov 25.

SARS-CoV-2 mRNA vaccination of aplastic anemia patients is safe and effective

Cilia R Pothast  1 , Kayleigh van Dijk  1 , Emma S Pool  1 , Constantijn J M Halkes  1 , Mirjam H M Heemskerk  1 , Jennifer M-L Tjon  1
Affiliations

SARS-CoV-2 mRNA vaccination of aplastic anemia patients is safe and effective

Cilia R Pothast et al. Am J Hematol. 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Authors declare that they have no competing interests.

Figures

FIGURE 1
FIGURE 1
Blood counts, humoral responses, and T‐cell responses following SARS‐CoV‐2 mRNA vaccination in aplastic anemia patients and healthy controls. (A) Hemoglobin, neutrophils, and thrombocytes shown pre‐vaccination, post‐vaccination (median 27.1 days after second vaccination), and at follow‐up (median 9.1 months after start vaccination). Blood value data at follow‐up were not available for three patients; therefore, the statistical comparisons of pre/post with follow‐up blood values were only performed for the 15 AA patients for whom data were available. (B) SARS‐CoV‐2 spike IgG response according to WHO standardization of AA patients (green; n = 18) and HCs (light blue; n = 9). The red dots correspond to individuals that were positive for SARS‐CoV‐2 IgG before vaccination. Post‐vaccination SARS‐CoV‐2 spike IgG levels were determined in serum of AA patients (median 27.1 days (range 11–49)) and HCs (median 21.4 days (range 18–24)) after second vaccination. Dotted line shows threshold of an adequate IgG response of 300 BAU/mL. (C) Percentage of SARS‐CoV‐2 spike‐specific CD4+ T‐cells of total CD4+ T‐cells pre‐ and post‐vaccination in AA patients (green) and HC (light blue). Dotted line shows a threshold for a CD4+ T‐cell response of 0.05%. (D) Percentage of SARS‐CoV‐2 spike‐specific CD8+ T‐cells of total CD8+ T‐cells pre‐ and post‐vaccination in AA patients (green) and HC (light blue). The percentage of SARS‐CoV‐2 spike‐specific CD4+ and CD8+ T‐cells was corrected for the background signal in the negative control (DMSO). Dotted line shows a threshold for a CD8+ T‐cell response of 0.025%. (E) The percentages of IFN‐γ, TNF‐α, and IL‐2 producing spike‐specific CD4+ T‐cells in AA patients (green) and HC (light blue). (F) The percentages of IFN‐γ and TNF‐α producing spike‐specific CD8+ T‐cells in AA patients (green) and HC (light blue). Horizontal bars in figures C‐F represent the median. ns: p > .05, *: p ≤ .05, **: p ≤ .01, ***: p ≤ .001. AA, aplastic anemia; HC, healthy controls; ns, not significant; LLoD, Lowest limit of detection; BAU, binding antibody units; DMSO, dimethyl sulfoxide; TNF‐α, tumor necrosis factor alpha; IFN‐γ, interferon gamma; and IL‐2, interleukin 2
See this image and copyright information in PMC

References

    1. Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen‐specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS‐CoV‐2 mRNA vaccination. Immunity. 2021;54(9):2133‐2142. - PMC - PubMed
    1. Young NS . Aplastic Anemia. New Engl J Med. 2018;379(17):1643‐1656. - PMC - PubMed
    1. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187‐207. - PubMed
    1. Walter J, Kricheldorf K, Isfort S, Brümmendorf TH, Panse J, Beier F. Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—a single center study. Eur J Haematol. 2022;108:528‐531. - PMC - PubMed